Printer Friendly

CLEOCIN VAGINAL CREAM, 2 PERCENT INTRODUCED TO TREAT BACTERIAL VAGINOSIS

CLEOCIN VAGINAL CREAM, 2 PERCENT INTRODUCED TO TREAT BACTERIAL VAGINOSIS
 KALAMAZOO, Mich., Aug. 13 /PRNewswire/ -- Cleocin Vaginal Cream, 2 percent (clindamycin phosphate) was introduced today as the only product for the treatment of bacterial vaginosis, the most common type of vaginal infection in women of reproductive age. The Upjohn Company (NYSE: UPJ) has marketed Cleocin products since 1972.
 Accounting for approximately one-third of all vaginal infections, bacterial vaginosis is essentially an overgrowth of the anaerobic bacteria in the vagina at the expense of normal lactobacilli. It is characterized by a whitish vaginal discharge, an unpleasant odor and minimal or no inflammation.
 Bacterial vaginosis has been formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, Corynebacterium vaginitis or anaerobic vaginosis.
 A clinical diagnosis of bacterial vaginosis is usually defined by the presence of a homogeneous vaginal discharge that a) has a pH greater than 4.5, b) emits a fishy, amine odor when mixed with 10 percent potassium hydroxide and c) contains clue cells upon microscopic examination. Gram's stain results should be consistent with the clinical diagnosis (markedly decreased lactobacillus, predominance of gardnerella, few or no white blood cells). Other pathogens commonly associated with vulvovaginitis, e.g., Trichomonas vaginalis, Chlamydia trachomatis, N. gonorrhoeae, Candida albicans, and Herpes simplex virus should be ruled out.
 Available by prescription, Cleocin Vaginal Cream, 2 percent comes with seven disposable applicators that are designed to allow proper vaginal administration of the cream. The recommended dosage is one full applicator (approximately 100 mg of clindamycin phosphate) inserted intravaginally once daily, preferably at bedtime, for seven consecutive days.
 Cleocin Vaginal Cream, 2 percent is contraindicated in individuals with a history of hypersensitivity to clindamycin, lincomycin or any of the components of the vaginal cream. It is also contraindicated in individuals with a history of regional enteritis, ulcerative colitis or a history of antibiotic-associated colitis. Approximately 16 percent of patients treated with Cleocin Vaginal Cream, 2 percent developed symptomatic cervicitis/vaginitis with 11 percent of patients developing vaginitis secondary to Candida albicans.
 The Upjohn Company is a worldwide, research-based provider of human health care products, animal health products, agronomic and vegetable seeds and specialty chemicals. Headquartered in Kalamazoo, the company has been dedicated to improving health and nutrition for more than a century.
 -0- 8/13/92
 /CONTACT: Laura B. Harwin of The Upjohn Company, 616-323-4501/
 (UPJ) CO: The Upjohn Company ST: Michigan IN: MTC SU: PDT


ML -- DE004 -- 9520 08/13/92 10:10 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 13, 1992
Words:408
Previous Article:SEARS OFFICIAL RETAILER OF NFL PUNT, PASS AND KICK PROGRAM
Next Article:INCOME OPPORTUNITY REALTY TRUST REPORTS SECOND QUARTER RESULTS
Topics:


Related Articles
CURATEK ANNOUNCES FDA APPROVAL OF NEW THERAPY FOR BACTERIAL VAGINOSIS
UPJOHN ACQUIRES RIGHTS TO MARKET ESTROGEN REPLACEMENT DRUG OGEN FROM ABBOTT
3M to Acquire Leading Gynecological Product
Searle's New, Once-Daily Flagyl ER (Metronidazole Extended Release Tablets) Receives FDA Clearance for Marketing
Searle's New, Once-Daily Flagyl ER (Metronidazole Extended Release Tablets) Receives FDA Clearance for Marketing
FDA Approves CLEOCIN(R) Vaginal Ovules for Treatment of Bacterial Vaginosis.
Intravaginal ring could be used in new approach to AIDS prevention.
Upsher-Smith Launches New Vandazole(TM) (Metronidazole Vaginal Gel, 0.75%) for Bacterial Vaginosis.
Mission Pharmacal Completes Phase III Study of Tindamax(R) for the Treatment of Bacterial Vaginosis.
Mission Pharmacal Submits Supplemental New Drug Application For Tindamax(R) (Tinidazole) as Treatment of Bacterial Vaginosis.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters